Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy

Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.

Original languageEnglish
Pages (from-to)397-400
Number of pages4
JournalJournal of Dermatology
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 2021

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint

Dive into the research topics of 'Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy'. Together they form a unique fingerprint.

Cite this